Rachel C Jankowitz, MD
Associate Professor of Clinical Medicine (Hematology-Oncology)
Director, Rena Rowan Breast Center , University of Pennsylvania
Section Chief, Breast Medical Oncology, Penn Medicine Abramson Cancer Center
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
South Pavilion, 10th Floor, Room 10-156
Philadelphia, PA 19104
South Pavilion, 10th Floor, Room 10-156
Philadelphia, PA 19104
Office: 215-615-5858
Fax: 215-615-5858
Fax: 215-615-5858
Education:
BA (Biology, Magna Cum Laude)
Fairfield University , 1999.
MD (Medicine)
Temple University School of Medicine , 2003.
Permanent linkBA (Biology, Magna Cum Laude)
Fairfield University , 1999.
MD (Medicine)
Temple University School of Medicine , 2003.
Description of Clinical Expertise
Breast Cancer, invasive lobular carcinoma, breast cancer clinical trials.Description of Research Expertise
Breast Cancer, invasive lobular carcinoma, breast cancer clinical trials.Selected Publications
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R.: NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 J Natl Compr Canc Netw 23(11): 426-436, Nov 2025 Notes: doi: 10.6004/jnccn.2025.0053.Kai Ding, Lyuqin Chen, Kevin M Levine, Matthew J Sikora, Nilgun Tasdemir, David Dabbs, Rachel Jankowitz, Rachel Hazan, Osama Shah, Jenny Atkinson, Adrian V Lee, Steffi Oesterreich: FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role. Breast Cancer Res Treat 211(2): 501-515, Jun 2025.
Peter Schmid 1, Javier Cortes 1, Rebecca Dent 1, Heather McArthur 1, Lajos Pusztai 1, Sherko Kümmel 1, Carsten Denkert 1, Yeon Hee Park 1, Rina Hui 1, Nadia Harbeck 1, Masato Takahashi 1, Seock-Ah Im 1, Michael Untch 1, Peter A Fasching 1, Marie-Ange Mouret-Reynier 1, Theodoros Foukakis 1, Marta Ferreira 1, Fatima Cardoso 1, Xuan Zhou 1, Vassiliki Karantza 1, Konstantinos Tryfonidis 1, Gursel Aktan 1, Joyce O'Shaughnessy 1; KEYNOTE-522 Investigators: Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391(21): 1981-1991, Nov 2024 Notes: KEYNOTE-522 investigators includes Rachel Jankowitz.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R.: Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(5): 331-357. Jul 2024.
Oesterreich S, Pate L, Lee AV, Chen F, Jankowitz RC, Mukhtar R, Metzger O, Sikora MJ, Li CI, Sotiriou C, Shah OS, Koorman T, Ulaner G, Reis-Filho JS, Davidson NM, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Derksen P, Bear T, Desmedt C.: International survey on invasive lobular breast cancer identifies priority research questions. NPJ Breast Cancer 10(1): 61, Jul 2024.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators.: Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J. Clin Oncol 42(31): 3652-3665. Jun 2024.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL.: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer. Breast Cancer Res 26(1): 69, Apr 2024.
Ding K, Chen L, Levine K, Sikora M, Tasdemir N, Dabbs D, Jankowitz R, Hazan R, Shah OS, Atkinson JM, Lee AV, Oesterreich S.: Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancer. bioRxiv [Preprint] Mar 2024 Notes: Preprint DOI: 10.1101/2024.03.18.585626
Van Baelen K, Van Cauwenberge J, Maetens M, Beck G, Camden A, Chase MC, Fraser V, Freeney S, Hutcheson L, Levine JK, Lien T, Terveer R, Turner C, Senkus E, Jankowitz RC, Vandecaveye V, Floris G, Neven P, Wildiers H, Sawyer E, Vincent-Salomon A, Derksen PWB, Desmedt C.: Reporting on invasive lobular breast cancer in clinical trials: a systematic review. NPJ Breast Cancer 10(1): 23, Mar 2024.
Sanft TB, Wong J, O'Neal B, Siuliukina N, Jankowitz RC, Pegram MD, Fox JR, Zhang Y, Treuner K, O'Shaughnessy JA. : Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. J Natl Compr Canc Netw. 22(2): 99-107, Mar 2024.